Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Shengbai is a traditional Chinese medicine (TCM) herbal formulation primarily used as an adjunct therapy to support patients undergoing chemotherapy, especially for the prevention and treatment of leukopenia (low white blood cell count) induced by chemotherapy. The decoction is reported to enhance immune function and improve hematopoietic recovery, thereby reducing the incidence of myelosuppression. Its mechanism is believed to involve modulation of immune responses and possibly regulation of microRNAs related to hematopoiesis[1]. The specific herbal composition may vary but typically includes classic TCM ingredients aimed at "strengthening vital energy" (Qi) and supporting blood production. Clinical studies suggest it can boost the effect of chemotherapy while mitigating some adverse effects such as leukopenia[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng shengbai.